A circular RNA derived from GLIS3 accelerates the proliferation of glioblastoma cells through competitively binding with miR-449c-5p to upregulate CAPG and GLIS3

Qingjiu Zhou1*, Mahati Shaya2, Yalikun Kugeluke3, Qiang Fu1, Shaoshan Li1 and Yisireyili Dilimulati1

Abstract
Background: Glioblastoma (GBM) is an aggressive and malignant brain tumor with extremely poor prognosis. Despite advances in treatment, the pathogenesis of GBM remains elusive. Mounting studies have revealed the critical role of circular RNAs (circRNAs) in the development and progression of human cancers including GBM, but the comprehension of their functions is still insufficient. In this study, we investigated the expression profile of a circRNA derived from GLIS family zinc finger 3 (GLIS3) in GBM and normal astrocytes. CircGLIS3 expression was detected through quantitative real-time polymerase chain reaction (qRT-PCR) analysis. Functional experiments were performed to analyze the influence of circGLIS3 on GBM cell proliferation and apoptosis. In addition, mechanism assays were to uncover the potential regulatory mechanism of circGLIS3.

Results: CircGLIS3 was up-regulated in GBM cells and knockdown of circGLIS3 significantly hampered proliferation and promoted apoptosis of GBM cells. Furthermore, circGLIS3 positively regulated CAPG and GLIS3 by sponging miR-449c-5p to affect GBM cell proliferation and apoptosis.

Conclusions: In summary, our study identified that circGLIS3 could promote proliferation and inhibit apoptosis of GBM cells via targeting miR-449c-5p/GLIS3/CAPG axis in vitro. This study could offer a novel molecular perspective for further investigation into mechanisms essential to GBM progression.

Keywords: circGLIS3, miR-449c-5p, CAPG, GLIS3, Glioblastoma

Introduction
As one of the most fatal neurologic cancers around the world, glioblastoma (GBM) has always been a difficult problem for the medical community [1]. Previous research has indicated that patients with GBM have a median survival of roughly 15 months, and the 5-year survival rate is about 5% [2]. Although advancement has been achieved in therapy of GBM, mortality caused by GBM is still significantly high [3]. Based on the current evidence, some molecular pathways are related to GBM pathogenesis, including small non-coding molecules like miR-21 [4], NF-kappaB pathway [5] and growth factor receptors [6]. However, rapid invasion of the brain parenchyma, resistance to conventional therapy and drug resistance severely lessen the effectiveness...
of treatment regimens [7]. Therefore, a better grasp of GBM pathogenesis is crucial for developing available therapeutic markers and targets [8–10].

In recent years, circular RNA (circRNA) becomes a rising focus in the field of biological research [11–14]. Compared with traditional linear RNAs, single-stranded, covalently closed circRNAs have a longer half-life and are more resistant to RNase R treatment, providing them the potential to serve as diagnostic biomarkers and therapeutic targets [15]. As circRNA molecules have a large number of miRNA binding sites, circRNAs can serve as miRNA “sponges”, which could competitively binding to miRNAs and lead to decreased functional miRNA molecules and up-regulation of target genes [16]. Via RNA sequencing, more than 80,000 circRNAs have been identified [13]. The association between circRNAs differentially expressed in GBM tissues, and the GBM progression has been unveiled [17]. For instance, circSCAF11 promotes GBM progression by sponging miR-421 and modulating SP1 and VEGFA [18]. Additionally, circDENND2A/miR-625-5p signaling can accelerate GBM development [19]. The above results demonstrated the importance of circRNAs in the development of GBM. However, to implement more precise therapy of GBM, more circRNAs need to be investigated [20]. Specifically, circGLIS3 (circ_0005890) has a length of 94,738 bp and the gene that codifies for circGLIS3 is located at chr9: 4,191,785–4,286,523. Previous study has identified that circGLIS3 was an oncogene in GBM [21]. Hinted by previous study unveiling that circGLIS3 could promote non-small cell lung cancer via regulating miR-644a/PTBP1 axis [22], we also intended to identify the functional role of circGLIS3 in GBM and figure out the underlying regulatory mechanism.

The interaction between circRNAs and their host genes has been found to play a crucial role in GBM. Specifically, circ-EPB41L5 could sponge miR-19a to regulate its host gene EPB41L5 to suppress GBM tumorigenesis [20]. GLIS3, the host gene of circGLIS3, is a member of GLI-similar zinc finger protein family and encodes a nuclear protein with five cysteine 2/histidine 2 (Cys2/His2) zinc finger domains [23]. Via binding with GLIS3-binding sites of target genes, GLIS3 can control gene transcription [24]. GLIS3 is overexpressed in several human organs, such as kidney, thyroid, and pancreas [25]. In this study, the potential involvement of GLIS3 in the regulatory mechanism of circGLIS3 in GBM cells was also explored. Capping actin protein, gelsolin-like (CAPG) encodes a member of the gelsolin/villin family of actin-regulatory proteins. Based on recent researches, CAPG was found to be overexpressed in GBM and could be a potential biomarker for GBM diagnosis [26]. Therefore, we also intended to investigate the potential correlation between circGLIS3 and CAPG in GBM cells.

In the current study, we aimed to verify the role of circGLIS3 in GBM cells and the relevant regulatory mechanism. Our findings will reveal a novel regulatory mechanism of circGLIS3 in GBM cells, contributing to better understanding of GBM.

Results

CircGLIS3 is up-regulated in GBM cells

According to previous study on circular RNA profiling in gliomas [27], circGLIS3 has been identified to be up-regulated in GBM tissues relative to deceased normal controls. CircBase database (http://www.circbase.org/) showed that there were 16 isoforms of circGLIS3. We utilized quantitative real-time polymerase chain reaction (qRT-PCR) analysis to detect the expression levels of the 16 isoforms in GBM cells and normal astrocytes (NHAs). The result of qRT-PCR clearly demonstrated that circ_0005890 was most aberrantly up-regulated in GBM cells (Additional file 1: Fig. S1A). Then, we designed experiments to validate whether circGLIS3 was a real circRNA. As shown in Additional file 1: Fig. S1B, circ_0005890 (circGLIS3) was derived from GLIS3 through back-spliced junction of intron 2, and the result of Sanger sequencing confirmed the head-to-tail splicing in the RT-PCR product of circGLIS3. After designing cDNA and gDNA primers for circGLIS3 and GAPDH on Primer-BLAST (https://www.ncbi.nlm.nih.gov/tools/primer-blast/), we conducted PCR-AGE assay. As was depicted in Additional file 1: Fig. S1C, circular transcript of circGLIS3 in cDNA but not gDNA was detected by divergent primers. Meanwhile, convergent primers magnified linear transcript from both cDNA and gDNA. Furthermore, linear GLIS3 mRNA but not circGLIS3 was digested by RNase R treatment (Additional file 1: Fig. S1D). To summarize, we found that as a real circRNA, circGLIS3 was up-regulated in GBM cell lines relative to the noncancerous cell line.

Knockdown of circGLIS3 inhibits the proliferation and promotes the apoptosis of GBM cells

To begin with, we obtained sh-circ#1/2 for knocking down circGLIS3 in U251 and LN229 cells. Additionally, to detect whether there was off-target effect of sh-circ#1/2, pcDNA3.1-circ was also procured to overexpress circGLIS3 in sh-circ#1/2 transfected cells. The overexpression efficiency was first detected through qRT-PCR (Additional file 1: Fig. S2A). As shown in Fig. 1A, compared with the control group, expression of circGLIS3 in U251 and LN229 cells transfected with sh-circ#1 and sh-circ#2 was much lower, and pcDNA3.1-circ co-transfection could completely rescue the decreased expression of
circGLIS3. Then, function experiments were conducted. From the result of cell counting kit-8 (CCK-8) assay, decline in cell viability was caused by transfection of sh-circ#1 and sh-circ#2, and pcDNA3.1-circ co-transfection could offset the effect (Fig. 1B). Moreover, 5-ethyl-2’-deoxyuridine (EdU) assay showed that upon sh-circ#1 or sh-circ#2 transfection, EdU positive cells were reduced, and the trend was rescued by circGLIS3 overexpression (Fig. 1C). Colony formation assay indicated that transfection of sh-circ#1/2 evidently inhibited the proliferation ability of cancer cells, and the inhibitory influence was countered by pcDNA3.1-circ co-transfection (Fig. 1D). Subsequently, we determined the apoptotic capability of cells via terminal deoxynucleotidyl transferase (TdT) dUTP nick-end labeling (TUNEL) assay. Based on the experimental results, we found that inhibition of circGLIS3 facilitated cell apoptosis, and pcDNA3.1-circ co-transfection countervalued the promoting effect (Fig. 1E). All results suggested that knockdown of circGLIS3 could weaken cell proliferation while strengthening cell apoptosis in GBM.

**CircGLIS3 regulates CAPG and GLIS3 in GBM cells**

In this part, we mainly investigated the regulatory mechanism of circGLIS3 in GBM cells. CircRNAs have been reported to regulate downstream mRNAs including their host genes to influence cell phenotype in cancers including gastric carcinoma, clear cell renal cell carcinoma and GBM [28–30]. Therefore, the potential correlation of circGLIS3 with CAPG, a promising biomarker of GBM [31], or with its host gene GLIS3 was then taken into consideration. According to Gene Expression Profiling Interactive Analysis (GEPIA) (http://gepia.cancer-pku.cn/) with data from The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx), CAPG and GLIS3 were both up-regulated in GBM tissues (Fig. 2A). As depicted in Additional file 1: Fig. S2B, both CAPG and GLIS3 were up-regulated in GBM cells. Subsequently, we continued to explore the relationship between circGLIS3 and CAPG and between circGLIS3 and GLIS3. Accordingly to fluorescence in situ hybridization (FISH) assay, co-localization of circGLIS3 and CAPG or GLIS3 in cytoplasm was confirmed (Fig. 2B). Previous studies have suggested that cytoplasmic circRNAs could function as a competing endogenous RNA (ceRNA) to sponge miRNAs and regulate mRNA expression [32, 33]. Therefore, circGLIS3 was hypothesized to regulate CAPG and GLIS3 via sponging certain miRNA. RNA-induced silencing complexes (RISCs) are formed by miRNA ribonucleoprotein complexes, which is present in anti-Ago2 immunoprecipitates, and anti-Ago2 immunoprecipitates contain miRNAs and their interacting RNA components [34]. On this basis, anti-Ago2 was used for conducting RNA binding protein immunoprecipitation (RIP) assay, and it was observed that circGLIS3, CAPG, and GLIS3 were all precipitated in RISCs, implying the potential involvement of a ceRNA network (Fig. 2C). Then, we found that when circGLIS3 in cells were knocked down, CAPG and GLIS3 mRNA levels were both reduced (Fig. 2D). For further confirmation, we examined the protein levels of CAPG and GLIS3 in U251 and LN229 cells with circGLIS3 knockdown or overexpression, respectively. A decrease in CAPG and GLIS3 protein levels was observed as a result of circGLIS3 silence, while circGLIS3 overexpression led to the opposite consequences (Additional file 1: Fig. S2C). In sum, circGLIS3 could positively regulate CAPG and GLIS3 in GBM cells.

**CircGLIS3 modulates CAPG and GLIS3 in GBM cells by sponging miR-449c-5p**

The specific ceRNA network of circGLIS3 was next explored. For further confirmation of the subcellular distribution of circGLIS3, subcellular fractionation experiment was first conducted and the result confirmed the major existence of circGLIS3 in cytoplasm (Fig. 3A). After searching on starBase (http://starbase.sysu.edu.cn/), we discovered that miR-449c-5p was the only miRNA potentially binding to circGLIS3, CAPG and GLIS3 (Fig. 3B). Binding sites between miR-449c-5p and circGLIS3, between miR-449c-5p and CAPG 3’UTR, and between miR-449c-5p and GLIS3 3’UTR were shown in Fig. 3C, and the mutant sequences were also illustrated in red. The result of RIP assay demonstrated that circGLIS3, miR-449c-5p, CAPG and GLIS3 were simultaneously precipitated in anti-Ago2, reflecting their co-existence in RISCs (Fig. 3D). In RNA pull down assay, miR-449c-5p was largely pulled down by biotinylated wild-type circGLIS3, biotinylated wild-type CAPG 3’UTR and biotinylated wild-type GLIS3 3’UTR, but not by their mutated forms (Fig. 3E). Luciferase reporter assay was then conducted with GBM cell lines (U251 and LN229) and NHAs for further verification of the indicated binding
Fig. 1 (See legend on previous page.)
Fig. 2 CircGLIS3 regulates CAPG and GLIS3 in GBM cells. A The expression levels of CAPG and GLIS3 in GBM tissue and normal deceased tissues were predicted from GEPIA database. B FISH was used to detect the co-localization of circGLIS3 and CAPG or GLIS3. C RIP assay accompanied with qRT-PCR analysis was carried out to investigate whether circGLIS3, CAPG, and GLIS3 were precipitated in the RISC. D QRT-PCR was performed to detect expression of CAPG and GLIS3 in GBM cells and NHAs with circGLIS3 knockdown. Student’s t-test was applied for statistical analysis in A/C while one-way ANOVA was applied for statistical analysis in D. *P < 0.05, **P < 0.01
Co-transfection of miR-449c-5p mimics weakened the luciferase activity in cells transfected with circGLIS3-Wt, CAPG 3’UTR-Wt or GLIS3 3’UTR-Wt constructs, while that of luciferase reporters carrying mutant sequences was hardly affected (Fig. 3F, G). Subsequently, we examined the influence of circGLIS3/miR-449c-5p on CAPG and GLIS3 expression via western blot assay. From the result, we could certify that CAPG and GLIS3 protein levels decreased in response to circGLIS3 depletion could be rescued by miR-449c-5p inhibition (Additional file 1: Fig. S2D). Then, functional experiments were carried out in a rescue way to test the influence of circGLIS3/miR-449c-5p on GBM cell proliferation and apoptosis. CCK-8, EdU and colony formation assay jointly reflected that miR-449c-5p overexpression could counteract the promoting effect of circGLIS3 upregulation on GBM cell proliferation (Additional file 1: Fig. S3A–C). TUNEL assay also evidenced that GBM cell apoptosis inhibited by circGLIS3 overexpression was offset by miR-449c-5p augment (Additional file 1: Fig. S3D).

In conclusion, circGLIS3 sponged miR-449c-5p to regulate CAPG and GLIS3 expression and affect GBM cell proliferation and apoptosis.

**CircGLIS3/miR‑449c‑5p/CAPG/GLIS3 axis regulates proliferation and apoptosis of GBM cells**

To further confirm the effect of circGLIS3/miR-449c-5p/CAPG/GLIS3 axis on GBM cells, we conducted functional experiments in a rescue way. Specifically, miR-449c-5p inhibitor (for miR-449c-5p inhibition), pcDNA3.1-CAPG (for CAPG overexpression) or pcDNA3.1-GLIS3 (for GLIS3 overexpression) was designed for the rescue experiments. CCK-8, EdU and colony formation assays were performed to analyze
proliferation ability of U251 and LN229 cells after indicated transfection. As shown in Fig. 4A–C, miR-449c-5p inhibition or overexpression of CAPG or GLIS3 reversed the attenuated proliferation ability of U251 and LN229 cells induced by circGLIS3 depletion. In addition, the promoting effect of circGLIS3 knockdown on GBM cell apoptosis could be counteracted by co-transfection of miR-449c-5p inhibitor, pcDNA3.1-CAPG or pcDNA3.1-GLIS3 (Fig. 4D). In summary, we confirmed that circGLIS3 affected the proliferation and apoptosis of GBM cells via miR-449c-5p/CAPG/GLIS3.

Discussion

Previous studies have demonstrated that in human cancer pathogenesis, circRNAs play important roles [35]. In GBM, the oncogenic or anti-oncogenic role of circRNAs in cancer progression has been found [36].

In this study, through the software prediction, many circRNAs were determined to be dysregulated [37]. Among these circRNAs, circGLIS3 was identified to be remarkably up-regulated in GBM tissues compared with non-tumor controls [37]. A total of 16 isoforms of circGLIS3 were confirmed on circBase. Circ_0005890 was the most up-regulated isoform of the 16 isoforms in GBM cell lines (U251 and LN229) in comparison with NHAs via qRT-PCR analysis (Additional file 1: Fig. S1). A series of functional assays demonstrated that knockdown of circGLIS3 attenuated the viability of GBM cell lines (Fig. 1). Qi et al. discovered that CAPG was the candidate biomarker of GBM [38]. CAPG was identified to be up-regulated in glioblastoma cell lines in previous study [26] and GLIS3 was found to be an overexpressed gene in GBM tissues [39]. GEPIA data also indicated that CAPG and GLIS3 were up-regulated in GBM tissues relative to deceased normal tissues (Fig. 2A). Additionally, the up-regulation of CAPG and GLIS3 in GBM cells relative to NHAs was validated via qRT-PCR analysis (Additional file 1: Fig. S2B). Considering that circGLIS3, CAPG, and GLIS3 were overexpressed in GBM tissues, we found that according to the results from FISH, RIP assay, and qRT-PCR, CAPG and GLIS3 were positively regulated by circGLIS3 and the three genes were co-localized in cell cytoplasm, implying the possibility of a ceRNA network (Fig. 2B–D). MiR-449c-5p served as a suppressor in many types of cancers, such as liver cancer [40], and gastric carcinoma [41]. However, whether miR-449c-5p played a role in GBM was obscure. After further confirming the major accumulation of circGLIS3 in cell cytoplasm (Fig. 3A), we searched on starBase and discovered that only miR-449c-5p was potential to bind with circGLIS3, CAPG, and GLIS3 (Fig. 3B). The binding correlation between miR-449c-5p and the three genes at the predicted sites was respectively validated via RIP assay, RNA pull down assay, and luciferase reporter assay (Fig. 3C–G).

Previous studies have unveiled the important role of circRNAs in human cancers, including GBM [42]. For example, GBM cell proliferation was promoted by circPTN to sponge miR-145-5p/miR-330-5p [43], and additionally, GBM angiogenesis was regulated by FUS/circ_002136/miR-138-5p/SOX13 signaling pathway [44]. It was suggested that circRNA targeted miRNA by acting as a miRNA sponge [45]. In view of the seriousness of GBM to threaten patients’ lives [46], we investigated into regulation of circGLIS3 in proliferation and apoptosis of GBM cells, with CAPG, GLIS3, and miR-449c-5p taken into consideration. In accordance to current study, it was suggested that circGLIS3/miR-449c-5p/CAPG/GLIS3 axis could regulate GBM cell proliferative and apoptotic capacities (Fig. 4).

Taken together, this paper mainly determined circGLIS3 played a role in GBM cell lines via sponging miR-449c-5p to up-regulate CAPG and GLIS3. The regulation of circGLIS3/miR-449c-5p/CAPG/GLIS3 axis was characterized in this research. Accumulating studies have uncovered that circRNAs contributing to stronger proliferation ability and weaker apoptosis ability of cancer cells are also validated to facilitate GBM tumorigenesis and progression in vivo [47, 48]. Moreover, the aberrant expression of genes has been suggested to relate to the prognosis of GBM patients [49, 50]. In this study, animal experiments and clinical samples were lacked, thus the role of circGLIS3 in GBM progression and the association between circGLIS3 expression and the prognosis of GBM patients with could not be investigated. Healthy control tissues were also unavailable at present, which is also a significant limitation of the current study. Therefore, larger-scale clinical research studies are needed to complete those tasks. Additionally, the association among circGLIS3, miR-449c-5p, CAPG, and GLIS3 was validated in both NHAs and GBM cells, indicating that it was not a cancer-specific relationship. Based on previous literature, NHAs could be driven towards a tumor-enhancing phenotype via some molecular networks [51]. Whether the modulatory network involving circGLIS3, miR-449c-5p, CAPG, and GLIS3 could affect the formation of malignant NHAs still needs to be elucidated with further experiments. However, this study still provides new thoughts to the regulatory mechanisms of circRNAs and a novel understanding of GBM pathogenesis.

Conclusions

The present study showed that circGLIS3 was up-regulated in GBM. The high expression of circGLIS3 led to stronger proliferation ability and weaker apoptosis ability of GBM cells. Knockdown of circGLIS3 suppressed
Fig. 4  CircGLIS3/miR-449c-5p/CAPG/GLIS3 axis suppresses proliferation of GBM cells.  

A  CCK-8 assay was carried out to detect cell viability of U251 and LN229 cells in different groups.

B  EdU assay was used to measure proliferation of U251 and LN229 cells under different conditions.

C  Colony formation assay was employed to detect proliferation of U251 and LN229 cells after transfection of different plasmids.

D  TUNEL assay was used to evaluate apoptosis of U251 and LN229 cells in different groups. One-way ANOVA was applied for statistical analysis. *P < 0.05, **P < 0.01
proliferation and advanced apoptosis of GBM cells. CircGLIS3 could exert its impacts on GBM cell proliferative and apoptotic capabilities via miR-449c-5p/CAPG/GLIS3 axis.

**Methods**

**Cell lines and cell culture**  
Human GBM cell lines U251 were acquired from The Cell Bank of Type Culture Collection of Chinese Academy of Sciences. Human GBM cell lines LN229 and normal human astrocytes (NHAs) were obtained from the American Type Culture Collection (Manassas, VA, USA). U251, LN229 and NHAs were incubated in DMEM supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin (Invitrogen). Cells were incubated in a condition with 5% CO2 at 37 °C.

**Cell transfection**  
For inhibition of expression, short hairpin RNAs (sh-RNAs) targeting circGLIS3 (sh-circ#1/2) and sh-NC (negative control) were constructed by GenePharma (Shanghai, China). Additionally, pcDNA3.1-circGLIS3, pcDNA3.1-CAPG and pcDNA3.1-GLIS3 were obtained for overexpression of circGLIS3, CAPG and GLIS3. NC mimics (the negative control), miR-449c-5p mimics and miR-449c-5p inhibitor (chemically modified, single-stranded RNA molecules designed to eliminate miR-449c-5p activity) were purchased from GenePharma (Shanghai, China). Transfecting the above plasmids into GBM cells (1 × 10^6) was implemented with the help of Lipofectamine 3000 (Invitrogen). All sequences of indicated transfection plasmids were provided in Additional file 3: Table S1.

**Bioinformatics analysis**  
circBase software [52] predicted that there were a total of 16 isoforms of circGLIS3. Primer-BLAST [53] was used to design primers of cDNA and gDNA of circGLIS3 (circ_0005890) and cDNA and gDNA of GAPDH. The expression of CAPG and GLIS3 in GBM and normal deceased tissues was obtained from GEPIA [54] based on data from TCGA and GTEx. The binding relation between different factors was predicted on starBase [55].

**Quantitative real-time PCR (qRT-PCR)**  
By using TRIzol reagent (Invitrogen), total RNA was extracted from cells (1 × 10^6). Via Bio-Rad CFX96 system (Bio-Rad, CA, USA) with SYBR-Green Real-Time PCR Kit (Toyobo, Osaka, Japan), qRT-PCR was performed. The utilization of Reverse Transcription Kit (Takara, Otsu, Japan) helped RNA to be reversely transcribed into cDNA. 2−ΔΔCT method was used to obtain the relative expressions. β-actin and U6 were used as internal references. All primer sequences and probe sequences, as well as NCBI Accession number of circGLIS3 isoforms, were provided in Additional file 4: Table S2.

**Western blot**  
Protein lysates were first obtained with RIPA buffer (R0278, Sigma-Aldrich, St. Louis, MO, USA), and PROTOT-1KT (KGP250, KeyGEN BioTECH, Nanjing, China) was used for extract of total protein, followed by measurement of protein concentration. Later, the proteins treated with SDS-PAGE (1610174, Bio-Rad Laboratories, Shanghai, China) were transferred to PVDF membranes (IPVH00010, Millipore, Bedford, MA, USA), which were blocked with 5% skimmed milk. Primary antibodies including anti-CAPG (HPA019080, Merck, Darmstadt, Germany), anti-GLIS3 (AV39924, Merck) and anti-GAPDH (T6442, Merck) were added for cultivation with membranes overnight at 4 °C and secondary antibodies (07-452, Merck) were then added for further cultivation. Eventually, the proteins were measured via enhanced chemiluminescence (ECL) detection system. Original data were provided in Additional file 2.

**Cell count kit-8 (CCK-8) assay**  
U251 and LN229 cells were placed onto 96-well plates at a density of 1000 cells per well. Optical density at 450 nm was measured after the addition of CCK-8 reagents (Biolite Biotech, Tianjin, China) at 24, 48, and 72 h.

**5-Ethynyl-2′-deoxyuridine (EdU) assay**  
U251 and LN229 cells (1 × 10^5) were placed onto 96-well plates with RPMI 1640 medium. Then, 100 μl 50 μM EdU reagent was added into the medium for 2-h incubation. Subsequently, paraformaldehyde was adopted to fix the cells and DAPI was used for nuclear staining. The percentage of EdU positive cells was analyzed and quantified through ImageJ.

**Colony formation assay**  
U251 and LN229 cells were put into plates with 6 wells (1000 cells per well) for incubation. Every 48 h, the medium needed to be changed. After 2-week incubation, the number of cell colonies was calculated manually.

**Terminal deoxynucleotidyl transferase (TdT) dUTP Nick-End labeling (TUNEL) assay**  
An in-situ cell death detection kit (Roche, Basel, Switzerland) was adopted to gauge cell apoptosis. In brief, 2.5 × 10^5 cells were blocked with H2O2 (3% in methanol) for 5 min and then labeled with TdT labeling reaction mix for 1 h at 37 °C. Nuclei exhibiting DNA fragmentation was visualized with DAPI for 15 min and observed under a light microscope (Olympus Corporation, Tokyo, Japan).
Luminometer (Promega), was used to measure the luminescence of circGLIS3 in cytoplasm and nucleus. PCR analysis was conducted to calculate the expression of references for cytoplasm and nucleus respectively. QRT-PCR fractions. β-actin and U6 were employed as internal references for cytoplasm and nucleus respectively. Nuclear-cytoplasmic fractionation

The subcellular localization of circGLIS3 in cells (1 × 10⁶). PARIS™ kit (Life Technologies, Inc, Gaithersburg, MD, USA) was used to isolate the nuclear and cytoplasmic RNA fractions. β-actin and U6 were employed as internal references for cytoplasm and nucleus respectively. QRT-PCR analysis was conducted to calculate the expression level of circGLIS3 in cytoplasm and nucleus.

Fluorescence in situ hybridization (FISH)

Hoechst33342 was used to stain nucleus. The RNA FISH probe mix used for circGLIS3, CAPG, and GLIS3 was designed separately. Subsequent to fixation with 4% paraformaldehyde at room temperature, 0.5% TritonX-100 was utilized to permeabilize the cells (5 × 10⁴) for 15 min at 4 °C, followed by PBS washes. Then, cells were co-cultured with the specific probes, and laser scanning confocal microscope (ZEISS) and ImageJ were utilized to analyze samples. Sequences for FISH probes targeting circGLIS3, GLIS3 and CAPG were provided in Additional file 5: Table S3.

Nuclear-cytoplasmic fractionation

On the premise of manufacturer’s protocol, we used nuclear-cytoplasmic fractionation to determine the subcellular localization of circGLIS3 in cells (1 × 10⁶). The well-cultured NHAs, U251 and LN229 (6 × 10⁷) were respectively lysed using lysis buffer, and then centrifuged. The subcellular localization of circGLIS3 in cells (1 × 10⁶). Nuclear-cytoplasmic fractionation

RNA binding protein immunoprecipitation (RIP) assay

RIP assay was conducted with RIP- Assay Kit (MBL Life Science, Shanghai, China). The well-cultured NHAs, U251 and LN229 (6 × 10⁷) were respectively lysed using lysis buffer, and then centrifuged. The protein-RNA complexes were purified and then quantified via qRT-PCR.

Luciferase reporter assay

The sequence of CAPG 3’UTR, GLIS3 3’UTR, or circGLIS3 containing miR-449c-5p binding sites (wild-type) was obtained with the help of bioinformatics tools, and the mutated sequence was chemically synthesized through site directed mutagenesis. Obtained sequences were inserted into pmirGLO luciferase vector (Promega, Madison, WI, USA) respectively. According to assay requirements, NHAs, U251 and LN229 (1 × 10⁸) were transfected with constructed plasmids and NC mimics or miR-449c-5p mimics. Dual Luciferase Reporter Assay System (Promega), with the support of GloMax® 20/20 Luminometer (Promega), was used to measure the luminescence. The relative luciferase activity was normalized to Renilla luciferase activity (internal control). Relevant sequences were provided in Additional file 6: Table S4.

RNA pull down assay

The purpose of RNA-RNA pull down assay was to detect potential binding relationship between miR-449c-5p and circGLIS3, GLIS3 3’UTR or CAPG 3’UTR. The biotin-labeled RNA probe targeting circGLIS3 was generated from GenScript Biotech Co., Ltd. (Nanjing, China). Bio-circGLIS3-WT and Bio-circGLIS3-Mut, as well as a biotinylated nonsense sequence as the negative control (Bio-NC), were mixed together with the lysate of U251 and LN229 cells (2 × 10⁴) for 2 h at 4 °C. Then, streptavidin magnetic beads were adopted to incubate with the complexes for 2 h. The level of miR-449c-5p was tested by qRT-PCR. All sequences in this assay were provided in Additional file 7: Table S5.

Statistical analysis

All representative assays were repeated at least three times. Values were presented as mean± standard deviation. Statistical analysis was evaluated by the unpaired Student’s t test or analysis of variance (ANOVA) by use of GraphPad Prism 7 (GraphPad Software, Inc., La Jolla, CA). P < 0.05 was thought to have statistical significance.

Abbreviations

GBM: Glioblastoma; circRNAs: Circular RNAs; GLIS3: GLIS family zinc finger 3; CAPG: Capping actin protein, gelsolin-like; NHAs: Normal human astrocytes; shRNAs: Short hairpin RNAs; NC: Negative control; qRT-PCR: Quantitative real-time PCR; CCK-8: Cell counting kit-8; EdU: 5-Ethynyl-2’-deoxyuridine; TdT: Terminal deoxynucleotidyl transferase; TUNEL: DUTP Nick-End Labeling; FISH: Fluorescence in situ hybridization; RIP: RNA binding protein immunoprecipitation; ANOVA: Analysis of variance; ceRNA: Competing endogenous RNA; GEPIA: Gene Expression Profiling Interactive Analysis; TCGA: The Cancer Genome Atlas; GTEx: Genotype-Tissue Expression.

Supplementary information

The online version contains supplementary material available at https://doi.org/10.1186/s12868-022-00736-6.

Additional file 1: Figure S1. Characterization of circGLIS3. Figure S2. Expression levels of CAPG and GLIS3 in GBM cells. Figure S3. Proliferation, migration and apoptosis of GBM cells with circGLIS3 overexpression or co-elevation on circGLIS3 and miR-449c-5p.

Additional file 2: Original gel blots for agarose gel electrophoresis (Figure S1C) and western blot (Figure S2C).

Additional file 3: Table S1. Sequences used for gene knockdown and overexpression.

Additional file 4: Table S2. Relevant sequences in qRT-PCR.

Additional file 5: Table S3. Sequences for FISH probes targeting circGLIS3, CAPG and GLIS3.

Additional file 6: Table S4. Sequences of plasmids in luciferase reporter assay.
References

1. Zhu F, Cheng C, Qin H, Wang H, Yu H. A novel circular RNA circENTPD7 contributes to glioblastoma progression by targeting ROS1. Cancer Cell Int. 2020;20:118.

2. Tamimi AF, Juweid M. Epidemiology and outcome of glioblastoma. In: De Vleeschouwer S, editor. Glioblastoma. Brisbane: Codon Publications; 2017.

3. Zhang G, Sun W, Zhu L, Feng Y, Wu L, Li T. Overexpressed circ_0029426 in glioblastoma forecasts unfavorable prognosis and promotes cell progression by sponging miR-197. J Cell Biochem. 2019;120(6):10295–302.

4. Masoudi MS, Mehrabian E, Mirzaei H. MiR-21: a key player in glioblastoma pathogenesis. J Cell Biochem. 2018;119(2):1285–90.

5. Pulyappadambam VT, Haranpaa KJ, Chakraborty S, Habib AA. The role of NF-kB in the pathogenesis of glioma. Mol Cell Oncol. 2014;1(3):e963478.

6. Wick W, Weller M, Weller M, Batshawel T, Yung AW, Platten M. Pathway inhibition: emerging molecular targets for treating glioblastoma. Neuro Oncol. 2011;13(6):566–79.

7. Zhang N, Wei L, Ye M, Kang C, You H. Treatment progress of immune checkpoint blockade therapy for glioblastoma. Front Immunol. 2020;11:592612.

8. Le Ruhn E, Preusser M, Roth P, Reardon DA, van den Bent M, Wen P, et al. Molecular targeted therapy of glioblastoma. Cancer Treat Rev. 2019;80:101896.

9. Ramos AD, Magge RS, Ramakrishna R. Molecular pathogenesis and emerging treatment for glioblastoma. World Neurosurg. 2018;116:495–504.

10. Shen A, Harish V, Afzal Z, Chijioka J, Kedir H, Dusmatova S, et al. MicroRNAs in glioblastoma multiforme pathogenesis and therapeutics. Cancer Med. 2016;5(8):1917–46.

11. Li X, Diao H. Circular RNA circ_0019946 acts as a competing endogenous RNA to inhibit glioblastoma progression by modulating miR-671-5p and CDR1. J Cell Physiol. 2019;234(8):13807–19.

12. Li R, Jiang J, Shi H, Qian H, Zhang X, Xu W. CircRNA: a rising star in gastric cancer. Cell Mol Life Sci. 2020;77(9):1661–80.

13. Li S, Teng S, Xu J, Su G, Zhang Y, Zhao J, et al. Microarray is an efficient tool for circRNA profiling. Brief Bioinform. 2019;20(4):1420–33.

14. Yu L, Liu Y. circRNA_0016624 could sponge miR-98 to regulate BMP2 expression in postmenopausal osteoporosis. Biochem Biophys Res Commun. 2019;516(2):546–50.

15. Zhou WY, Cai ZR, Liu J, Wang DS, Hu HQ, Xu RH. Circular RNA: metabolism, functions and interactions with proteins. Mol Cancer. 2020;19(1):172.

16. Zhang Z, Yang T, Xiao J. Circular RNAs: promising biomarkers for human diseases. Ebiomedicine. 2018;34:267–74.

17. Barbagallo D, Caponnetto A, Ciniglierio M, Brex D, Barbagallo C, D’Angeli F, et al. CircSMARCA5 induces migration of glioblastoma multiforme cells by regulating a molecular axis involving splicing factors SRSF1/5/SRSF3/SP2. Int J Mol Sci. 2018;19(2):480.

18. Meng Q, Li S, Liu Y, Zhang S, Jin J, Zhang Y, et al. Circular RNA circSCAF11 accelerates the glioma tumorigenesis through the miR-421/SP1/VEGFA axis. Mol Thera Nucleic Acids. 2019;7:669–77.

19. Su H, Zou D, Sun Y, Dai Y. Hypoxia-associated circDENND2A promotes glioma aggressiveness by sponging miR-625-5p. Cell Mol Biol Lett. 2019;24:24.

20. Lv T, Miao Y, Xu T, Sun W, Sang Y, Jia F; et al. Circ-EPB41L5 regulates the host gene EPB41L5 via sponging miR-19a to repress glioblastoma tumorigenesis. Aging. 2020;12(1):318–39.

21. Liu J, Zhao K, Huang N, Zhang N. Circular RNAs and human cancer. Cancer Biol Med. 2019;16(1):11–23.

22. Wu Z, Jiang H, Fu H, Zhang Y. A circGLIS3/miR-644a/PTBP1 positive feedback loop promotes the malignant biological progressions of non-small cell lung cancer. Am J Cancer Res. 2021;11(1):108–22.

23. Chou CK, Tang CJ, Chou HL, Liu CY, Ng MC, Chang YT, et al. The potential role of Kruppel-like zinc-finger protein GLIS3 in genetic diseases and cancers. Arch Immunol Ther Exp. 2017;65(5):381–9.

24. Jeon K, Kumar D, Conway AE, Park K, Jothi R, Jetten AM. GLIS3 transcriptionally activates WNT genes to promote differentiation of human embryonic stem cells into posterior neural progenitors. Stem Cells (Dayton, Ohio). 2019;37(2):202–15.

25. Wen X, Yang Y. Emerging roles of GLIS3 in neural tube defects. Cell Mol Life Sci. 2016;73(20):3687–83.

26. Yang G, Zhang Y, Yang J. Identification of potentially functional CircRNA-miRNA-mRNA regulatory network in gastric carcinoma using bioinformatics analysis. Med Sci Monit. 2019;25:8777–96.

27. Song X, Zhang N, Han P, Moon BS, Lai RK, Wang K, et al. Circular RNA profi in gliomas revealed by identification tool UROBORUS. Nucleic Acids Res. 2016;44(9):e87.

28. Yang G, Zhang Y, Yang J. Identification of potentially functional CircRNA-miRNA-mRNA regulatory network in gastric carcinoma using bioinformatics analysis. Med Sci Monit. 2019;25:8777–96.

29. Bai S, Wu Y, Yan Y, Shao S, Zhang L, Liu J, et al. Construct a circRNA/miRNA/mRNA regulatory network to explore potential pathogenesis and therapy options of clear cell renal cell carcinoma. Sci Rep. 2020;10(1):13659.

30. Chen B, Wang M, Huang R, Liao K, Wang T, Yang R, et al. Circular RNA circLGMN facilitates glioblastoma progression by targeting miR-127-3p/PTB axis. Cancer Lett. 2021;522:225–37.

31. Scoville DW, Kang HS, Jetten AM. GLIS3-1: emerging roles in reprogramming, stem and progenitor cell differentiation and maintenance. Stem Cell Investig. 2017;4:80.
32. Mitra A, Pfeifer K, Park KS. Circular RNAs and competing endogenous RNA (ceRNA) networks. Transl Cancer Res. 2018;7(Suppl 5):S624–8.

33. Tang Q, Chen Z, Zhao L, Xu H. Circular RNA hsa_circ_0000515 acts as a miR-326 sponge to promote cervical cancer progression through up-regulation of Elk1. Aging. 2019;11(22):9982–99.

34. Zhao CC, Jiao Y, Zhang YY, Ning J, Zhang YR, Xu J, et al. Lnc SMAD5-AS1 as ceRNA inhibits proliferation of diffuse large B cell lymphoma via Wnt/B-catenin pathway by sponging miR-135b-Sp to elevate expression of APC. Cell Death Dis. 2019;10(4):252.

35. Xu H, Zhang B, Yang Y, Li Z, Zhao P, Wu W, et al. LncRNA MIR4435-2HG potentiates the proliferation and invasion of glioblastoma cells via modulating miR-1224-Sp/TGFBR2 axis. J Cell Mol Med. 2020;24(11):6362–72.

36. Barbagallo D, Caponnetto A, Brex D, Mirabella F, Barbagallo C, Lauretta G, et al. CircSMARCA5 regulates VEGFA mRNA splicing and angiogenesis in glioblastoma multiforme through the binding of SRG1. Cancers. 2019;11(2):194.

37. Zhao C, Gao Y, Guo R, Li H, Yang B. Microarray expression profiles and bioinformatics analysis of miRNAs, lncRNAs, and circRNAs in the secondary temozolomide-resistant glioblastoma. Invest New Drugs. 2019;38:1227–35.

38. Yang Q, Wang R, Wei B, Peng C, Wang L, Hu G, et al. Candidate biomarkers and molecular mechanism investigation for glioblastoma multiforme utilizing WGCNA. Biomed Res Int. 2018;2018:4246703.

39. Cooper LA, Gutman DA, Long Q, Johnson BA, Cholleti SR, Kurc T, et al. The proneural molecular signature is enriched in oligodendrogliomas and predicts improved survival among diffuse gliomas. PLoS ONE. 2010;5(9):e12548.

40. Sandbothe M, Buurman R, Reich N, Greiwe L, Türker, et al. The microRNA-449 family inhibits TGF-β-mediated liver cancer cell migration by targeting SOX4. J Hepatol. 2017;66(5):1012–21.

41. Wu Z, Wang H, Fang S, Xu C. MiR-449c inhibits gastric carcinoma growth. Life Sci. 2015;137:14–9.

42. Qian L, Guan J, Wu Y, Wang Q. Upregulated circular RNA circ_0074027 promotes glioblastoma cell growth and invasion by regulating miR-518a-Sp/LTIF1 signaling pathway. Biochem Biophys Res Commun. 2019;510(4):515–9.

43. Chen J, Chen T, Zhu Y, Li Y, Zhang Y, Wang Y, et al. circPTN sponges miR-145-Sp/miR-330-Sp to promote proliferation and stemness in glioma. J Exp Clin Cancer Res. 2019;38(1):398.

44. He Z, Ruan X, Liu X, Zheng J, Liu Y, Liu L, et al. FUS/circ_002136/miR-138-Sp/50X13 feedback loop regulates angiogenesis in Glioma. J Exp Clin Cancer Res. 2019;38(1):65.

45. Lu Y, Deng X, Xiao G, Zheng X, Ma L, Huang W. circ_0001730 promotes proliferation and invasion via the miR-326/Wnt7B axis in glioma cells. Epigenomics. 2019;11(11):1335–52.

46. Chi G, Yang F, Xu D, Liu W. Silencing hsa_circ_PVT1 (circPVT1) suppresses the growth and metastasis of glioblastoma multiforme cells by up-regulation of miR-199a-Sp. Antit Cells Nanomed Biotechnol. 2020;48(1):188–96.

47. Wu Z, Zheng M, Zhang Y, Xie M, Tian S, Ding T, et al. Hsa_circ_0043278 functions as competitive endogenous RNA to enhance glioblastoma multiforme progression by sponging miR-638. Aging. 2020;12(21):21114–28.

48. Wang Q, Zheng D, Li Y, Zhang Y, Sui R, Chen Y, et al. Circular RNA circ_0001588 sponges miR-21-1-Sp to facilitate the progression of glioblastoma via up-regulating YY1 expression. J Gene Med. 2021;23(10):e3371.

49. Yang X, Niu S, Liu J, Fang J, Wu Z, Ling L, et al. Identification of an epithelial-mesenchymal transition-related lncRNA prognostic signature for patients with glioblastoma. Sci Rep. 2021;11(1):23694.

50. Dahlrot RH, Bangsø JA, Petersen JK, Rosager AM, Sørensen MD, Reifenberger G, et al. Prognostic role of Ki-67 in glioblastomas excluding contribution from non-neoplastic cells. Sci Rep. 2021;11(1):17918.

51. Agnihotri S, Wolf A, Munoz DM, Smith CJ, Gajadhar A, Restrepo A, et al. A GATA4-regulated tumor suppressor network represses formation of malignant human astrocytomas. J Exp Med. 2011;208(4):689–702.

52. Glazar P, Papavasileiou P, Rajewsky N. circBase: a database for circular RNAs. RNA. 2014;20(11):1666–70.

53. Ye J, Coulouris G, Zaretskaya I, Cutcutache I, Rozen S, Madden TL. Primer-BLAST: a tool to design target-specific primers for polymerase chain reaction. BMC Bioinform. 2012;13:134.